HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dutch Pandemic-Related Sales Boost Peaks In 2021, Pharmacy Rout Continues

Executive Summary

The Netherlands' OTC market stabilizes in 2021, after defying the negative impacts of COVID-19 seen in other major European markets the year before. Consumers continued to flock to drugstores and supermarkets rather than pharmacies, highlighting the ongoing structural transformation of the country's consumer health market.

You may also be interested in...



COVID VMS Boom Driving Shift To Self-Care As The Netherlands Bucks 2020 Sales Trends

Despite the pandemic, the Dutch OTC market recorded impressive growth of 4.6% in 2020. HBW Insight speaks to Bernard Mauritz, director of the Netherlands' self-care industry association, Neprofarm, about how the country bucked negative sales trends seen in other European OTC markets. 

As Botanicals Deadlock Holds Back Investment, Dutch Industry Takes The Initiative

Dutch self-care industry association, Neprofarm, has updated the way it self-regulates botanical health claims in an effort to rebuild confidence in the country's herbal food supplements market. 

Dutch OTC Market in 2019: VMS Delisting Accelerates Shift Towards Self-Care

A delisting of vitamin D and calcium food supplements accelerates a long-term shift towards self-care among Dutch consumers, according to the latest market data from local industry association, Neprofarm, in collaboration with IQVIA. 

Topics

Latest News
UsernamePublicRestriction

Register

RS152518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel